Node negative patients (T1-4 N0 M0) | Node positive patients (T1-4 N1-2 M0) | |||||||
---|---|---|---|---|---|---|---|---|
Total | Events | % | p Value | Total | Events | % | p Value | |
Median observation time for disease free survival, 82 months. Statistical calculation using log rank test. | ||||||||
Univariate statistical calculation using χ2 test. | ||||||||
Receptor status: positive, ER positive and/or PR positive; negative, ER negative and PR negative; detection by immunohistochemistry. | ||||||||
ER, oestrogen receptor; NS, not significant; PCNA, proliferating cell nuclear antigen; PR, progesterone receptor. | ||||||||
Age (years) | ||||||||
< 50 | 47 | 9 | 19.2 | 55 | 25 | 45.5 | ||
> 50 | 83 | 23 | 27.7 | NS | 104 | 61 | 58.7 | NS |
Menopausal status | ||||||||
Pre | 35 | 6 | 17.1 | 46 | 22 | 47.8 | ||
Peri | 21 | 4 | 19.1 | 20 | 10 | 50.0 | ||
Post | 74 | 22 | 29.7 | NS | 93 | 54 | 58.1 | NS |
Tumour size (cm) | ||||||||
< 2 | 63 | 14 | 13.0 | 47 | 19 | 40.4 | ||
2–5 | 59 | 16 | 27.1 | 80 | 43 | 53.8 | ||
> 5 | 8 | 2 | 25.0 | NS | 32 | 24 | 75.0 | < 0.00001 |
Tumour grade | ||||||||
GI | 23 | 3 | 13.0 | 23 | 9 | 39.1 | ||
GII | 72 | 20 | 27.8 | 80 | 35 | 43.8 | ||
GIII | 35 | 9 | 25.7 | NS | 56 | 42 | 75.0 | < 0.00001 |
Receptor status | ||||||||
Negative | 38 | 12 | 31.6 | 52 | 38 | 73.1 | ||
Positive | 90 | 19 | 21.1 | NS | 104 | 47 | 45.2 | 0.00001 |
PCNA | ||||||||
< 10% | 62 | 13 | 21.0 | 65 | 27 | 41.5 | ||
10–49% | 43 | 10 | 23.4 | 47 | 28 | 59.6 | ||
> 50% | 22 | 8 | 36.4 | NS | 44 | 29 | 65.9 | 0.037 |
Her2/neu | ||||||||
Negative | 102 | 24 | 23.5 | 116 | 56 | 48.3 | ||
Positive | 25 | 7 | 28 | NS | 38 | 29 | 76.3 | 0.0017 |
p53 | ||||||||
Negative | 82 | 18 | 22.0 | 87 | 40 | 46.0 | ||
Positive | 46 | 13 | 28.3 | NS | 67 | 44 | 65.7 | 0.005 |
p21waf | ||||||||
Negative | 87 | 23 | 26.4 | 107 | 63 | 58.9 | ||
Positive | 43 | 9 | 20.9 | NS | 52 | 23 | 44.2 | NS |
Total | 130 | 32 | 24.6 | 159 | 86 | 54.1 |